Business Context and Reporting Period
This Form 8-K was filed by Pacira Pharmaceuticals, Inc. on March 4, 2019. The filing reports the entry into a Material Definitive Agreement to acquire MyoScience, Inc. Upon closing, the Company intends to change its name to Pacira BioSciences, Inc. to reflect its diversified business.
Key Financial Metrics and Transaction Terms
The filing details a merger agreement with the following financial terms:
- Initial Consideration: Approximately $120.0 million in cash for all outstanding equity interests of MyoScience, subject to customary post-closing adjustments.
- Milestone Payments: Up to an additional $100.0 million payable upon achievement of specific regulatory and commercial milestones.
- Payment Structure: Up to 50% of certain 2020 milestone payments may be paid in Pacira common stock at the option of MyoScience securityholders.
- Funding Source: The Company expects to fund the acquisition from cash on hand.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes
The primary material change is the execution of the Merger Agreement to acquire MyoScience, Inc. This transaction represents a strategic expansion of the Company's portfolio. No other material changes to financial position or operations were reported in this specific filing.
Outlook, Risks, and Contingencies
- Closing Conditions: The transaction is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Termination Rights: The Merger Agreement includes termination rights for both parties subject to specific conditions.
- Representations and Warranties: The filing notes that representations and warranties in the agreement are negotiated for risk allocation and may not reflect the actual state of facts regarding the businesses.
Investor Verification Checklist
- Verify the Company's current cash on hand to confirm the ability to fund the $120.0 million initial purchase price.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific definitions of the regulatory and commercial milestones triggering the $100.0 million in potential additional payments.
- Monitor the status of the Hart-Scott-Rodino antitrust waiting period to assess the likelihood and timing of the closing.
- Confirm the timeline for the corporate name change from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc.